



Cancer Reporting in California

Appendix G **Codes for Casefinding**

California Cancer Reporting System Standards, Volume I: Abstracting and Coding Procedures

Twenty-Fourth Edition

Version 1.0, July 2024

Prepared By:

California Cancer Registry

Cancer Informatics and IT Systems Unit

Editors:

Mary K. Brant, B.S., ODS-C

Donna M. Hansen, ODS-C

Janine Smith, B.S., ODS-C

State of California:

Department of Health Services

Dr. Mark Damesyn, CDRSB, Chief

Appendix G: Codes for Casefinding

This appendix includes the current Screening List of ICD-10-CM Codes for Casefinding as well as links to historical lists.

Effective for Cases diagnosed between October 1, 2023 and September 30, 2024

Screening List of ICD-10-CM Codes for Casefinding

Certain ICD-10-CM* codes used by medical records departments for discharge diagnoses identify cases of malignant neoplasms that are reportable to the California Cancer Registry. Case finding procedures must include the review of medical records coded with the following numbers. Newly reportable diseases are followed by the ICD-O-3 morphology and behavior code in parentheses.

Reportable Neoplasms

ICD-10-CM Code	Explanation of ICD-10-CM Code
C00.- - C43.-, C4A.-, C45.- - C48.-, C49.- -C96.-	Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies
C44.00, C44.09	Unspecified/other malignant neoplasm of skin of lip
C44.10-, C44.19-	Unspecified/other malignant neoplasm of skin of eyelid
C44.13-	Sebaceous cell carcinoma of skin of eyelid, including canthus
C44.20-, C44.29-	Unspecified/other malignant neoplasm skin of ear and external auricular canal
C44.30-, C44.39-	Unspecified/other malignant neoplasm of skin of other/unspecified parts of face
C44.40, C44.49	Unspecified/other malignant neoplasm of skin of scalp & neck
C44.50-, C44.59-	Unspecified/other malignant neoplasm of skin of trunk
C44.60-, C44.69-	Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder
C44.70-, C44.79-	Unspecified/other malignant neoplasm of skin of lower limb, including hip
C44.80, C44.89	Unspecified/other malignant neoplasm of skin of overlapping sites of skin
C44.90, C44.99	Unspecified/other malignant neoplasm of skin of unspecified sites of skin
C49.A-	Gastrointestinal Stromal Tumor
D00.- - D05. -, D07.- - D09	In-situ neoplasms <i>Note 1: Excludes carcinoma in situ tumors of the cervix (D06. _)</i> <i>Note 2: Excludes prostatic Intraepithelial neoplasia ((PIN III) of the prostate. Other Insitu histologies are reportable</i> <i>Note 3: For D04 (carcinoma in situ of skin), excludes basal and squamous cell in situ lesions.</i>
D18.02	Hemangioma of intracranial structures and any site

D32.-	Benign neoplasm of meninges (cerebral, spinal and unspecified)
D33.-	Benign neoplasm of brain and other parts of central nervous system
D35.2 - D35.4	Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland
D42.-, D43.-	Neoplasm of uncertain or unknown behavior of meninges, brain, CNS
D44.3 - D44.5	Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland
D45	Polycythemia vera (9950/3) ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1)
D46.-	Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9989,9993)
D47.02	Systemic mastocytosis
D47.1	Chronic myeloproliferative disease (9963/3, 9975/3) <i>ICD-10-CM Coding instruction note: Excludes the following:</i> <ul style="list-style-type: none"> • <i>Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_)</i> • <i>Chronic myeloid leukemia BCR/ABL-positive (C92.1_)</i> • <i>Myelofibrosis & Secondary myelofibrosis (D75.81)</i> • <i>Myelophthisic anemia & Myelophthisis (D61.82)</i>
D47.3	Essential (hemorrhagic) thrombocythemia (9962/3) <i>Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia</i>
D47.4	Osteomyelofibrosis (9961/3) <ul style="list-style-type: none"> • <i>Includes: Chronic idiopathic myelofibrosis</i> • <i>Myelofibrosis (idiopathic) (with myeloid metaplasia)</i> • <i>Myelosclerosis (megakaryocytic) with myeloid metaplasia)</i> • <i>Secondary myelofibrosis in myeloproliferative disease</i>
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3)
D47.Z-	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3) <i>Note: Effective 1/1/2021, PLTD (9971/3) is no longer reportable (9971/1)</i>
D49.6, D49.7	Neoplasm of unspecified behavior of brain, endocrine glands and other CNS
D72.11-	Hypereosinophilic syndrome [HES] (9964/3)
K31.A22	Gastric intestinal metaplasia with high grade dysplasia
N85.02	Endometrial intraepithelial neoplasia [EIN]
R85.614	Cytologic evidence of malignancy on smear of anus
R87.614	Cytologic evidence of malignancy on smear of cervix
R87.624	Cytologic evidence of malignancy on smear of vagina

R90.0	Intracranial space-occupying lesion found on diagnostic imaging of central nervous system
-------	---

***Note:** Beginning with cases diagnosed 1/1/2023, pilocytic astrocytoma are coded 9421/1. Cases diagnosed prior to 1/1/2023 are coded 9421/3.

SUPPLEMENTAL LIST ICD-10-CM* (EFFECTIVE DATES 10/1/2023-09/30/2024)

Note: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, other reportable diseases and treatment related information.

- The codes included in this supplemental have changed. During a major review, many of the codes previously included were found to not be necessary and were removed
 - All codes previously included can be found in the ICD-10-CM Casefinding List, 2022

Supplemental Codes

ICD-10-CM Code

Explanation of ICD-10-CM Code

D06.-	Carcinoma in situ of the cervix
D13.7	Benign neoplasm of endocrine pancreas <i>Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2</i> <ul style="list-style-type: none"> • Islet cell adenoma • Nesidioblastoma • Islet cell adenomatosis • Insulinoma • Beta cell adenoma
D21.4	Benign neoplasm of connective and other soft tissue of abdomen <i>Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2</i> <i>Gastrointestinal stromal tumor, NOS/GIST, NOS/Gastrointestinal autonomic nerve tumor/GANT/Gastrointestinal pacemaker cell tumor (8936/1, now 8936/3)</i>
D23.9	Other benign neoplasm of skin Benign carcinoid tumors of other sites <i>Note: Effective 1/1/2021: Review these codes to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O-3.2</i> <ul style="list-style-type: none"> • Aggressive digital papillary adenoma (c44) (8408/1, but now 8408/3)
D35.0-	Benign neoplasm of adrenal gland

	<p><i>Note: Effective 1/1/2021: Review this code to look for the following which was previously a benign (8700/0) tumor of the adrenal gland, but is now malignant per ICD-O-3.2(8700/3)</i></p> <ul style="list-style-type: none"> • <i>Pheochromocytoma</i> • <i>Adrenal medullary paraganglioma</i> • <i>Chromaffin paraganglioma</i> • <i>Chromaffin tumor</i> • <i>Chromaffinoma</i>
D37.8	<p>Neoplasm of uncertain behavior of other specified digestive organs (includes uncertain behavior of pancreas)</p> <p><i>Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</i></p> <ul style="list-style-type: none"> • <i>Pancreatic endocrine tumor, NOS (C259, 8150/1, now 8150/3)</i> • <i>Islet cell tumor, NOS (C259, 8150/1, now 8150/3)</i> • <i>Glucagonoma, NOS (C259, 8152/1, now 8152/3)</i> • <i>Alpha cell tumor, NOS (C259, 8152/1, now 8152/3)</i> • <i>Glucagon-like peptid-producing tumor (C259, 8152/1, now 8152/3)</i> • <i>Somastostatinoma, NOS (8156/1, now 8156/3)</i> • <i>Somatostatin cell tumor, NOS (8156/1, now 8156/3)</i> • <i>Endocrine tumor, functioning, NOS (8158/1, now 8158/3)</i> <p>ACTH-producing tumor (8158/1, now 8158/3)</p>
D3A.-	<p>Benign carcinoid tumors of other sites</p> <p><i>Note: Effective with 1/1/2021: Review these codes to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O-3.2</i></p> <ul style="list-style-type: none"> • <i>Carcinoid tumor, argentaffinoma, NOS (8240/1, now 8241/3)</i> • <i>Enterochromaffin-like cell carcinoid, NOS (8242/1, now 8241/3)</i>
D44.6	<p>Neoplasm of uncertain behavior carotid artery</p> <p><i>Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</i></p> <ul style="list-style-type: none"> • <i>Carotid body tumor/Carotid body paraganglioma (8692/1, now 8692/3)</i>
D44.7	<p>Neoplasm of uncertain behavior of aortic body and other paraganglia</p> <p><i>Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</i></p> <ul style="list-style-type: none"> • <i>Paraganglioma, NOS (8680/1, now 8680/3)</i> • <i>Sympathetic paraganglioma (8681/1, now 8681/3)</i> • <i>Parasympathetic paraganglioma (8682/1, now 8682/3)</i> • <i>Glomulus jugulare tumor, NOS/jugular paraganglioma/juglotympanic paraganglioma (8690/1, now 8690/3)</i>

	<ul style="list-style-type: none"> • <i>Aortic body tumor/aortic body paraganglioma/aorticopulmonary paraganglioma (8691/1, now 8691/3)</i> • <i>Extra-adrenal paraganglioma, NOS/nonchromaffin paraganglioma, NOS/chemodectoma (8693/1, now 8693/3)</i>
D48.0	<p>Neoplasm of uncertain behavior of bone and articular cartilage</p> <p><i>Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</i></p> <ul style="list-style-type: none"> • <i>Clear cell odontogenic tumor (9341/1, now 9341/3)</i>
D48.1	<p>Neoplasm of uncertain behavior of connective and other soft tissue of abdomen</p> <p><i>Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2</i></p> <p><i>Gastrointestinal stromal tumor, NOS/GIST, NOS/Gastrointestinal autonomic nerve tumor/GANT/Gastrointestinal pacemaker cell tumor (8936/1, now 8936/3)</i></p>
D49.2	<p><i>Neoplasm of unspecified behavior of digestive organs (includes unspecified behavior of pancreas)</i></p> <p><i>Note: Review this code to look for the following which were previously unknown behavior tumors of the pancreas, but are now malignant tumors per ICD-O-3.2 (Histology 8150/3)</i></p> <ul style="list-style-type: none"> • <i>Pancreatic endocrine tumor, NOS</i> • <i>Islet cell tumor, NOS</i>
D61.810	Antineoplastic chemotherapy induced pancytopenia
D64.81	Anemia due to antineoplastic chemotherapy
D70.1	Agranulocytosis secondary to cancer chemotherapy
D72.10	Eosinophilia, NOS (Note: Screen for incorrectly coded Chronic eosinophilic leukemia, 9964/3)
D75.81	Myelofibrosis (Note: this is not primary myelofibrosis (9961/3))
E31.2-	Multiple endocrine neoplasia [MEN] syndromes
E34.0	Carcinoid syndrome
E88.3	Tumor lysis syndrome (following antineoplastic chemotherapy)
G89.3	Neoplasm related pain (acute)(chronic)
H47.42	Disorders of optic chiasm in (due to) neoplasm
47.52-	Disorders of visual pathways in (due to) neoplasm
H47.63-	Disorders of visual cortex in (due to) neoplasm
I31.31	Malignant pericardial effusion in diseases classified elsewhere
J70.0	Acute pulmonary manifestations due to radiation

J70.1	Chronic and other pulmonary manifestations due to radiation
J91.0	Malignant pleural effusion
K12.31	Oral mucositis (ulcerative) due to antineoplastic therapy
K12.33	Oral mucositis (ulcerative) due to radiation
K52.0	Gastroenteritis and colitis due to radiation
K62.7	Radiation proctitis
K62.82	Dysplasia of anus (AIN I and AIN II)
K92.81	Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy)
L58.-	Radiodermatitis
L59.8	Other disorders of skin and subcutaneous tissue related to radiation
L59.9	Disorder of the skin and subcutaneous tissue related to radiation, unspecified
M31.11	Hematopoietic stem cell transplantation-associated thrombotic microangiopathy
M96.2	Postradiation kyphosis
M96.5	Postradiation scoliosis
N30.4	Irradiation cystitis
N46.024	Azoospermia due to radiation
N46.124	Oligospermia due to radiation
N52.31-N52.32, N52.34-N52.36	Post procedural erectile dysfunction (due to prostatectomy, cystectomy, radiation)
O35.6-	Maternal care for (suspected) damage to fetus by radiation
O9A.1-	Malignant neoplasm complicating pregnancy, childbirth and the puerperium (conditions in C00-C96)
P04.11	Newborn affected by maternal antineoplastic chemotherapy
P04.12	Newborn affected by maternal cytotoxic drugs
Q85.0-	Neurofibromatosis (nonmalignant) (9540/1) <i>Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable</i>
R18.0	Malignant ascites
R53.0	Neoplastic (malignant) related fatigue
R97.21	Rising PSA following treatment for malignant neoplasm of prostate
T38.6-	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified
T38.8-, T38.9-	Poisoning by hormones and their synthetic substitutes

T45.1-	Poisoning by, adverse effect of and under dosing of antineoplastic and immunosuppressive drugs
T45.8-, T45.9-	Poisoning by primary systemic and hematological agent, unspecified
T66	Unspecified effects of radiation
T80.81-	Extravasation of vesicant agent
T80.82-	Complication of immune effector cellular therapy <ul style="list-style-type: none"> • Complication of chimeric antigen receptor (CAR-T) cell therapy
T86.0-	Complications of bone marrow transplant
Y63.2	Overdose of radiation given during therapy
Y84.2	Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Z08	Encounter for follow-up examination after completed treatment for malignant neoplasm (medical surveillance following completed treatment)
Z40.0-	Encounter for prophylactic surgery for risk factors related to malignant neoplasms
Z42.1	Encounter for breast reconstruction following mastectomy
Z48.290	Encounter for aftercare following bone marrow transplant
Z48.3	Aftercare following surgery for neoplasm
Z51.0	Encounter for antineoplastic radiation therapy
Z51.1-	Encounter for antineoplastic chemotherapy and immunotherapy
Z51.5, Z51.89	Encounter for palliative care and other specified aftercare
Z79.63-	Long term (current) use of chemotherapeutic agent
Z79.64	Long term (current) use myelosuppressive agent (hydroxyurea)
Z79.81-	Long term (current) use of agents affecting estrogen receptors and estrogen levels
Z85.-	Personal history of malignant neoplasm
Z86.00-	Personal history of in situ neoplasm
Z86.010	Personal history of colonic polyps
Z86.011	Personal history of benign neoplasm of the brain
Z86.012	Personal history of benign carcinoid tumor
Z92.21, Z92.23, Z92.25, Z92.3	Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation)
Z92.850	Personal history of Chimeric Antigen Receptor T-cell therapy <ul style="list-style-type: none"> • Personal history of CAR-T-cell therapy

Z94.81, Z94.84	Bone marrow and stem cell transplant status
----------------	---

^International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2024